Trial reportCell reports. Medicine2025
Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.
Abstract readClinical Trial, Phase II
In one paragraph
Trial report in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study.Journal for immunotherapy of cancer · 2026Trial
- Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation.Journal for immunotherapy of cancer · 2025Trial
- GeneInsight: Condensing gene set knowledge via language models.PLoS computational biology · 2026Article
- Regulatory B-cell states in NSCLC immunotherapy resistance: mechanisms, spatial context and translational implications.Cancer immunology, immunotherapy : CII · 2026Review
- Review
- Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models.Scientific reports · 2026Article
- Peripheral blood biomarkers for predicting response to PD-1/PD-L1 inhibitors.Biomarker research · 2026Review
- PRECOG update: an augmented resource of clinical outcome associations with gene expression for adult, pediatric, and immunotherapy cohorts.Nucleic acids research · 2026Article
- Comparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patients.Oxford open immunology · 2026Article
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
- From peripheral blood to tumor microenvironment: spatial dimension deficiency and paradigm reconstruction in immunotherapy biomarker research.Frontiers in immunology · 2026Review
- Integrated peripheral blood multi-omics profiling identifies immune signatures predictive of neoadjuvant PD-1 blockade efficacy in head and neck squamous cell carcinoma.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Wee Loong ChinNational Centre for Asbestos Related Diseases, Institute for Respiratory Health, Nedlands, WA 6009, Australia; Medical School, University of Western Australia, Crawley, WA 6009, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia.
Alistair M CookNational Centre for Asbestos Related Diseases, Institute for Respiratory Health, Nedlands, WA 6009, Australia; School of Biomedical Sciences, University of Western Australia, Crawley, WA 6009, Australia.
Jonathan CheeNational Centre for Asbestos Related Diseases, Institute for Respiratory Health, Nedlands, WA 6009, Australia; School of Biomedical Sciences, University of Western Australia, Crawley, WA 6009, Australia.
Nicola PrincipeNational Centre for Asbestos Related Diseases, Institute for Respiratory Health, Nedlands, WA 6009, Australia; School of Biomedical Sciences, University of Western Australia, Crawley, WA 6009, Australia.
Tracy S HoangNational Centre for Asbestos Related Diseases, Institute for Respiratory Health, Nedlands, WA 6009, Australia; School of Biomedical Sciences, University of Western Australia, Crawley, WA 6009, Australia.
Joel KidmanNational Centre for Asbestos Related Diseases, Institute for Respiratory Health, Nedlands, WA 6009, Australia; School of Biomedical Sciences, University of Western Australia, Crawley, WA 6009, Australia.
Khaing P W HmonHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, WA 6009, Australia.
Yen YeowHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, WA 6009, Australia.
Matthew E JonesHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, WA 6009, Australia.
Rui HouHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, WA 6009, Australia.
Elena DenisenkoHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, WA 6009, Australia.
Alison M McDonnellNational Centre for Asbestos Related Diseases, Institute for Respiratory Health, Nedlands, WA 6009, Australia; School of Biomedical Sciences, University of Western Australia, Crawley, WA 6009, Australia; The Kids Research Institute, University of Western Australia, Nedlands WA 6009, Australia.
Chung-Chau HonRIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa 230-0045, Japan.
Jonathan MoodyRIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa 230-0045, Japan.
Denise AndersonThe Kids Research Institute, University of Western Australia, Nedlands WA 6009, Australia.
Sonia YipNational Health and Medical Research Council, Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
Michelle M CumminsNational Health and Medical Research Council, Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
Martin R StocklerNational Health and Medical Research Council, Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
Peey-Sei KokNational Health and Medical Research Council, Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
Chris BrownNational Health and Medical Research Council, Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
Thomas JohnDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Steven C-H KaoDepartment of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia.
Deme J KarikiosDepartment of Medical Oncology, Nepean Hospital, Kingswood, NSW, Australia.
Kenneth J O'ByrneDepartment of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Brett G M HughesRoyal Brisbane and Women's Hospital, Brisbane, QLD, Australia; School of Medicine, University of Queensland, Brisbane, QLD, Australia.
Richard A LakeNational Centre for Asbestos Related Diseases, Institute for Respiratory Health, Nedlands, WA 6009, Australia; Medical School, University of Western Australia, Crawley, WA 6009, Australia.
Alistair R R ForrestHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, WA 6009, Australia. Electronic address: alistair.forrest@gmail.com.
Anna K NowakNational Centre for Asbestos Related Diseases, Institute for Respiratory Health, Nedlands, WA 6009, Australia; Medical School, University of Western Australia, Crawley, WA 6009, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia. Electronic address: anna.nowak@uwa.edu.au.
Timo LassmannThe Kids Research Institute, University of Western Australia, Nedlands WA 6009, Australia. Electronic address: timo.lassmann@thekids.org.au.
W Joost LesterhuisNational Centre for Asbestos Related Diseases, Institute for Respiratory Health, Nedlands, WA 6009, Australia; School of Biomedical Sciences, University of Western Australia, Crawley, WA 6009, Australia; The Kids Research Institute, University of Western Australia, Nedlands WA 6009, Australia. Electronic address: willem.lesterhuis@uwa.edu.au.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers to guide treatment decisions. Here, we combine time course RNA sequencing (RNA-seq) of peripheral blood mononuclear cells with pre-treatment tumor transcriptome data from the single-arm, phase 2 DREAM trial (N = 54). Single-cell RNA-seq and T cell receptor sequencing (TCR-seq) reveal that CD8
Indexed as
Biomarkers, TumorImmunotherapyMesotheliomaAgedCD8-Positive T-LymphocytesFemaleHumansLeukocytes, MononuclearMaleMiddle AgedNeoplasmsTranscriptomeTumor MicroenvironmentBiomarkers, TumorbiomarkerscancerCD8(+) T effector memory cellsICTimmune checkpoint therapymesotheliomaPD-L1peripheral bloodplatinum chemotherapyresponsesingle-cell RNA sequencing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.